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Background: Sub-Saharan Africa remains the epicenter of the HIV pandemic.  In South Africa 35.8% 
of maternal deaths are ascribed to non-pregnancy related infections, namely HIV infection. The 
prevalence rate of HIV in pregnancy in KwaZulu-Natal is an estimated 37.7%. Furthermore, in women 
of reproductive age, the incidence of HIV infection is high (18.8%).  The shallow trophoblast invasion 
and the lack of physiological conversion of the spiral arteries into small bore low resistance conduits is 
the primary cause behind the pathogenesis of pre-eclampsia. HIV-positive patients on HAART are 
predisposed to pre-eclampsia development. Trophoblast cells are stimulated to invade the maternal 
decidua by interacting cytokines and growth factors in the local environment through signal transduction 
pathways. Aberrant cell signaling and signaling molecule function impedes trophoblast invasion 
necessary for a healthy pregnancy, leading to endothelial dysfunction. As a result, the expression of cell 
signaling analytes may potentially be a predictive biomarker for patients at risk to pre-eclamptic 
development. This study investigated expression of STAT-3 and MEK-1 in HIV-associated pre-
eclampsia, as a diagnostic tool of abnormal placentation in pre-eclampsia. 
Method: Venous blood samples of 40 normotensive and 40 pre-eclamptic patients further stratified by 
HIV status were collected at a large regional hospital for buffy coat extraction, followed by analysis of 
cell signalling analytes by the Bio-Plex Multiplex immunoassay.  
Results: The downregulation of both STAT-3 and MEK-1 expression was observed in pre-eclamptic 
pregnancies irrespective of HIV status, respectively (p < 0.05; p = 0.1526). No significance for STAT-3 
(p = 0.0859) was detected between HIV-positive and HIV-negative groups irrespective of pregnancy 
type, although a lowered trend was observed in the HIV-positive group. Contrary to expected outcomes, 
MEK-1 expression was significantly decreased (p = 0.0102) in the HIV-positive group, irrespective of 
pregnancy type.  
Conclusion: This study demonstrated the downregulation of STAT-3 and MEK-1 expression in pre-
eclampsia, corroborating a defective trophoblast invasion. The decreased expression of STAT-3 in HIV-
infection may be attributed to HAART and/or to the reduced expression of IL-6 that stimulates STAT-3 
phosphorylation. It is also plausible to assume that the downregulation of MEK-1 arises from non-
phosphorylation of HIV-regulatory proteins. Additional studies, are required to further investigate the 
role of signal transduction pathways and its effect on HAART in pre-eclampsia development.  









































LITERATURE AND BACKGROUND REVIEW 
 
1.1 HIV/AIDS  
 
The Human Immunodeficiency Virus causes immunosuppression and is the leading global health crisis. 
Research on the pathogenesis, transmission and prevention strategies of the virus have evolved, yet a cure 
to the disease remains elusive (Simon et al., 2006). 
 
1.1.1 Epidemiology of HIV/AIDS 
 
Globally, there are an estimated 36.7 million people living with HIV-1 infection, with approximately 35 
million people having died from AIDS related diseases. Antiretroviral therapy has been administered to 
19.5 million people (UNAIDS, 2016). Statistics reveal that in 2016, approximately 1.8 million new HIV-1 
infections emerged (UNAIDS, 2016). These estimates indicate the vigorous nature of this rapidly evolving 
epidemic, in relation to epidemiology, magnitude, viral diversity and modes of transmission (Inciardi and 
Williams, 2005). 
 
1.1.2 HIV/AIDS in Southern Africa 
 
Southern Africa is the epicentre of the HIV/AIDS pandemic with new HIV-1 infections continuously 
emerging (Hayes and Weiss, 2006).  South Africa has the highest prevalence (12.7%) of HIV 
infection/AIDS in the world, with 7.03 million HIV-positive individuals (Statistics, 2016). Contributing 
factors to the spread of HIV include poverty, inequality and an unstable social environment, increasing rates 
of sexually transmitted infections, limited access to quality medical care and poor control and guidance in 
response to the disease (Zuma et al., 2016). KwaZulu-Natal is considered the epicentre of this burden, with 
the highest prevalence (19.8%) amongst the provinces (Statistics, 2016). 





1.1.3 HIV/AIDS amongst adolescent females 
 
Approximately 70% of infected women live in sub-Saharan Africa. In general, 25-30% of all new HIV-1 
infections occur in young adults (<25 years) (Dellar et al., 2015).  In South Africa, this percentage is a 
translation of 113 000 new infections in young women annually, which is four-times more than the infection 
occurring in men (Dellar et al., 2015).  However, HIV prevalence among the youth aged 15-24 yrs has 
declined to 5.6% in 2016. The greatest difference exists in this 15-24 age group, where for every one man 
infected, 3 women become infected. This is a serious dilemma for obstetricians as one-fifth of South African 
women in their reproductive age are HIV positive (Statistics, 2016). 
The driving force behind the age-sex disparity in HIV acquisition is the increasing prevalence of young 
girls engaging in sexual activities with older men (Dellar et al., 2015). In addition to the age-sex disparity 
in HIV acquisition, the biological factors which also contribute to HIV acquisition includes large surface 
area of the genital mucosa, single layer of the immature cervical mucosa; increasing levels of activating 
immune cells in the female genital tract, increasing expression of co-receptors of HIV in cervical cells in 
comparison to foreskin cells and a mucosal surface with an increased likelihood of acquiring micro-
abrasions during sexual practices (Dellar et al., 2015). 
Furthermore, research has shown a link between HIV infection and hypertensive disorders in pregnancy 




Hypertensive disorders in pregnancy, contributes a large proportion of morbidity and mortality rates 
worldwide (Uzan et al., 2011). Pre-eclampsia is the development of hypertension and proteinuria during 
the second half of gestation in a woman who was previously healthy and normotensive (Huppertz, 2008).  





The set of criteria that defines PE is characterized by new onset high blood pressure (≥140/90 mmHg) 
together with excessive protein (≥300mg protein) in urine during the second trimester (20 weeks) of 
pregnancy with/without oedema (Magnussen et al., 2007). In South Africa, hypertensive disorders of 
pregnancy account for 14% of maternal deaths (Saving Mothers Report, 2013). 
Pre-eclampsia may also be classified according to gestational period. Early onset pre-eclampsia (EOPE) 
develops before 34 weeks of pregnancy and late onset pre-eclampsia (LOPE) develops at or after 34 weeks 
of pregnancy (Raymond and Peterson, 2011). EOPE is regarded as the more severe form and is considered 
as a fetal disorder. LOPE on the other hand, is considered as a maternal disorder and is associated with a 
normal functioning placenta, an increasing placental volume, normal growth of the fetus, normal birth 
weight and more favourable maternal and neonatal outcomes (Raymond and Peterson, 2011). 
 
1.2.1 Epidemiology of pre-eclampsia 
 
Approximately 7 – 10% of pregnancies worldwide are complicated by PE. The primary cause of maternal 
mortality in developing countries is PE exacerbated by limited health care accessibility. The only solution 
to PE is premature delivery of the placenta (Kalumba et al., 2013). According to the World Health 
Organization (WHO), the burden of PE in developing countries is approximately seven times greater than 
that in developed countries (Osungbade and Ige, 2011). African countries such as Ethiopia, Tanzania and 
Egypt have a pre-eclamptic incidence rate that ranges from 1.8% - 7.1% (Osungbade and Ige, 2011). In 
South Africa, 83% of maternal deaths emanating from hypertension (14.8%) is attributed to PE 
development. In KwaZulu-Natal the prevalence of pre-eclampsia is 12% (Saving Mothers Report, 2013). 
There are a number of predisposing factors to PE development such as bacterial infection, immune 
maladaptation, inflammatory response and cytokine dysregulation (Perez-Sepulveda et al., 2014). A 
mothers’ risk of developing pre-eclampsia is influenced by age, primigravidae, primi-paternity, obesity, a 





medical history of chronic conditions including hypertension; diabetes; kidney disease; frequent migraines; 
lupus; thrombophilia, and characteristics of pregnancy such as a molar or twin pregnancy, previous history 
of PE or fetal abnormality (Uzan et al., 2011). Women aged above 40 years are at a higher risk of developing 
PE. The risk of PE also increases as the interval between pregnancies increase (English et al., 2015). 
Furthermore, chronic conditions and obesity, specifically hypertension, predisposes the mother to a higher 
risk of PE development (English et al., 2015). 
Pre-eclampsia development can be attributed to a strong familial disposition of the disorder. Research has 
shown that normotensive women related to first-degree relatives with PE, are 5 times more likely to develop 
PE than second-degree relatives (Valenzuela et al., 2012). Additionally, paternal genes are also thought to 
play a role in developing PE, as evidenced by an increased risk of PE in women involved with men that 
have previously been involved in pre-eclamptic pregnancies (Valenzuela et al., 2012). Paternal genes in PE 
are of significant importance from a genetic aspect, as these genes play a role in controlling trophoblast 
invasion and placental growth (Valenzuela et al., 2012).  
 
1.2.2 Pathogenesis of pre-eclampsia 
 
The placenta is the fundamental organ to a healthy pregnancy. To effectively achieve healthy growth and 
development of the fetus, the placenta is required to bring the circulation of the fetus and mother into close 
contact, thus normal placentation is required for a successful pregnancy (Gude et al., 2004).  
Extravillous trophoblast cells (EVT) proliferate from the tips of the anchoring chorionic villi, and after the 
first 2 weeks of gestation in a precisely timed sequence, columns of EVT cells invade the maternal decidua 
and into the inner myometrium. These invasive EVT cells are termed interstitial EVTs. Some EVT cells 
merge into the walls of the spiral arteries and are referred to as intramural trophoblasts (Van Der Spuy, 
2002). 





In another pathway, some trophoblast cells migrate through the lumen of the spiral artery, a process called 
endovascular invasion. This process of remodeling includes replacing the endothelium and media smooth 
muscle cells, replacing internal elastic lamina resulting in loss of elasticity, dilation of the arteries to wide 
bore sinusoids and the loss of vasomotor control (Raymond and Peterson, 2011). Therefore, the invasion 
of EVT cells influences the transformation of the high resistant muscular spiral arteries into distended, 
flaccid vessels of high capacitance and low resistance, enabling sufficient blood perfusion thereby 
sustaining the nutrient and oxygen demands of the fetus (Raymond and Peterson, 2011).   
In PE however, placentation is inadequate (Naicker et al., 2003) as seen in figure 1, when comparing normal 
and abnormal pregnancies. Spiral artery remodeling is limited to the decidua. The myometrial artery lumen 
remains of small calibre and of high resistance. A state of under-perfusion persists, resulting in placental 
hypoxia and localised oxidative stress. This leads to a systemic inflammatory response causing endothelial 








Figure 1: Normal placentation vs abnormal placentation (adapted from The Eunice Kennedy 
Shriver National Institute of Child Health and Human Development, 2017). 
 
The enhanced maternal inflammatory response and dysfunction of endothelial cells is caused by the release 
of secretory factors from the maternal circulation including anti-angiogenic factors, apoptotic debris and 
inflammatory cytokines (Cindrova-Davies, 2009). Evidence has shown that the secretion of these factors is 





induced by hypoxia and oxidative stress which have significant influence in the pathology of PE (Cindrova-
Davies, 2009). The clinical manifestations of PE presented after 20 weeks of gestation occur as a result of 
the failure of spiral artery remodeling by trophoblast invasion (Hladunewich et al., 2007). 
 
1.2.3 Aetiology of pre-eclampsia 
 
One of the key elements in the pathogenesis of PE is oxidative stress, which causes the activation of 
signaling pathways hence the release of toxic and soluble factors into the maternal circulation (Cindrova-
Davies, 2009). Reactive oxygen species (ROS) produced by the mitochondria are formed as a result of 
partially reduced molecular oxygen under normal physiological conditions. Oxidative stress usually results 
from excessively produced ROS, dysfunctional mitochondria or an impaired antioxidant system (Nita and 
Grzybowski, 2016). The overproduction of ROS intimidates the anti-oxidant defense mechanisms of the 
placenta, leading to a reduced anti-oxidant potential, as the maternal circulation of pre-eclamptic women 
contains a decreased concentration of ascorbic acid (Hubel, 1999). Despite the role of ROS in oxidative 
stress, strong evidence indicates that the defective conversion of the spiral arteries, subsequently results in 
placental insufficiency, the primary initiator of oxidative stress (Cindrova-Davies, 2009).  
Moreover, the deficient trophoblast invasion in PE may be triggered by a modified maternal immune 
response or a defect in the maternal tolerance to the semi-allogeneic fetus (Perez-Sepulveda et al., 2014). 
Many groups have indicated that in the decidua, pre-eclamptic patients demonstrate an excessive activation 
of monocytes and neutrophils. Upon activation, these monocytes are spontaneously involved in the 
increased synthesis of pro-inflammatory cytokines including IL-1b, IL-6, and IL-8. Dendritic cells, CD4+, 
CD8+ T-lymphocytes and natural killer cells have a pro-inflammatory response in PE, rather than an anti-
inflammatory and immuno-tolerant response in normal pregnancies (Perez-Sepulveda et al., 2014). 
 
 





1.2.4 HIV associated pre-eclampsia 
 
HIV infection is associated with immune suppression (Kalumba et al., 2013) whilst in normal pregnancies 
there is a slight elevation in the maternal immune response to the fetal allograft. In PE however, there is an 
exacerbation of this response (Perez-Sepulveda et al., 2014). Conflicting data on whether HIV infection 
increases, decreases or neutralises PE development exists (Hall, 2007). Also, highly active antiretroviral 
therapy (HAART) seems to influence pre-eclampsia development (Kalumba et al., 2013). HAART re-
establishes immunocompetence in the infected individual, thus resulting in an active and improved immune 
response which leads to an increased susceptibility to PE, in comparison to a failing immune system in 
HIV-negative women which pre-eclampsia cannot thrive on (Kalumba et al., 2013; Maharaj et al., 2017). 
In light of the fact that both HIV infection and PE is high in South Africa, it is urgent that the relationship 
of this duality be investigated. 
 
1.3 Cell signaling pathways 
 
Cells and tissues express a variety of distinct receptor combinations that activate signaling pathways 
involved in regulating key biological processes such as cell proliferation, migration, invasion and apoptosis 
(Yang et al., 2014). Cell signaling begins through the binding of a signaling molecule to a cell surface 
receptor, and ends when DNA of the cell expresses a protein resulting in cell modulation (Rébé et al., 2013). 
A contributing factor relating to the modulation of apoptosis and invasion of trophoblast cells are cell 
signaling pathways, hence it is important elucidate their role in HIV-associated pre-eclampsia. 
 
1.3.1 JAK-STAT signal transducing pathway 
 
The migratory and invasive properties of EVT cells are functionally controlled by a surplus of cytokines 
and growth factors that commonly signal through the Janus kinase-signal transducer and activator of 





transcription (JAK-STAT) pathway (Fitzgerald et al., 2008). The mammalian JAK family is constituted of 
four members, JAK-1, JAK-2, JAK-3 and TYK2. The mammalian STAT family comprises seven members, 
STAT-1, STAT-2, STAT-3, STAT-4, STAT-5A, STAT-5B AND STAT-6 (Shuai and Liu, 2003). STAT-
3 exists as an inactive cytoplasmic form in cells (Rébé et al., 2013). Upon activation, STAT-3 translocates 
from the cytoplasm to the nucleus where it binds to cognate sequences of DNA, here it serves as a 
transcription activator for a vast array of genes (Zhang et al., 2015).  
Figure 2: JAK-STAT activation (adapted from Fitzgerald et al., 2008). 
 
Upon cytokine binding to inner receptor ligands in figure 2, JAKs activate and undergo phosphorylation 
resulting in activation of inner receptor ligands. Inactive STATs bind to inner receptor ligands to be 
phosphorylated by JAKs, resulting in their activation. Activated STATs dissociate and dimerize, to 
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1.3.1.1 The role of STAT-3 
 
During placentation, cytokines produced by trophoblast cells influence their migration and invasion. Such 
cytokines include the Hepatocyte growth factor (HGF), Interleukin-6 (IL-6), Interleukin-11 (IL-11) and the 
Leukemia inhibitory factor (LIF) that signal through the JAK-STAT pathway (Fitzgerald et al., 2008). The 
STAT-3 activating subunit plays a fundamental role in trophoblast invasion. In fact, phosphorylated STAT-
3 enhances the invasive capabilities of trophoblast cells in vitro, which is necessary for a successful 
pregnancy (Zhang et al., 2015). 
Expression of HGF promotes the invasive potential of trophoblast cells, as invasion is directly proportional 
to HGF dosage (Fitzgerald et al., 2008). It has been suggested that a lack of HGF production causes PE, as 
a study by Kauma et al., 1999 revealed pre-eclamptic women had been associated with decreased 
production of HGF (Fitzgerald et al., 2008). The IL-11 receptor located on interstitial trophoblast cells are 
known to boost their migratory capabilities without influencing their role in proliferation, and this is 
accomplished by the stimulation of phosphorylated STAT-3 (Fitzgerald et al., 2008). Cytotrophoblasts 
express high levels of IL-6, leading to the increased activity of proteins viz., MMP-9 and MMP-2 that are 
significantly involved in invasion and implantation in pregnancy (Fitzgerald et al., 2008).  
 
1.3.1.2 Inhibitors of STAT-3 activity 
 
Negative regulators of the JAK-STAT pathway include the suppressor of cytokine signaling (SOCS) 
proteins, the protein inhibitor of activated STAT (PIAS) and protein tyrosine phosphates (PTPs) (Shuai and 
Liu, 2003). SOC proteins are immunolocalized to the syncytiotrophoblasts and it is postulated that a 
decrease in SOC activity may influence the overexpression of SOCS in pre-term labour (Fitzgerald et al., 
2008). It is also possible that inflammatory cytokines occurring in infections during pre-term labour, could 
be responsible for the elevated levels of SOC expression (Fitzgerald et al., 2008). 





The shortcomings of STAT-3 activity in trophoblast invasion may subsequently provoke the development 
of PE during placental development, because as placental apoptosis is increased, trophoblast cell invasion 
is concurrently decreased within the placental bed (Naicker et al., 2013; Zhang et al., 2015). 
 
1.3.2 The MAPK/ERK pathway 
 
The mitogen activated protein kinase (MAPK) pathway consists of the MAP kinase kinase kinase 
(MAP3K), MAP kinase kinase (MAPKK) and MAPK tier cascades involved in transmitting signals to 
target molecules to initiate the required physiological process (Figure 3; Shaul and Segar, 2007). Each tier 
of the pathway is composed of various protein kinases that phosphorylate from an upstream receptor, to a 
downstream target (Shaul and Seger, 2007). The extracellular regulated kinase (ERK) cascade is the main 
downstream component of the MAPK pathway (Shaul and Seger, 2007). ERK is activated by dual specific 
kinases MEK-1 and MEK-2. Activated ERK induces cell proliferation, differentiation and development 
and under certain conditions, cell survival, migration and apoptosis (Shaul and Seger, 2007). 
 
                                                               Stimulus            Growth Factors 
 
 
                                                              MAPKKK:                  Raf 
 
 
                                                              MAPKK:                 MEK 1/2  
 
 
                                                              MAPK:                    ERK 1/2  
                                              Cellular response:               Proliferation, development, differentiation,   
                                                                                            survival 
Figure 3: Schematic of the MAPK tier cascade and respective kinases for each pathway (adapted 
from Cowan & Storey, 2013). 





1.3.2.1 The role of MEK-1 
 
The MEK groups are three mammalian isoforms (MEK-1, MEK-1b and MEK-2) that share an 85% 
homology. MEK-1 is activated through the phosphorylation of residues SER218 and SER222 in the MEK-
1 activation loop. In addition to being ERK activators, MEKs are stimulated to translocate to the nucleus 
of resting cells (Zheng and Guan, 1994). 
MEK-1 plays a role in trophoblast invasion as a result of the invasive capabilities of EVT cells being tightly 
regulated throughout pregnancy, by various growth and regulatory factors within the microenvironment of 
the uterine endometrium and decidua (Graham and Lala, 1991). In most cells, sphingosine kinases play a 
role in the phosphorylation of sphingosine-1-phosphate (S1P) (Liu et al., 2012). S1P is a signaling molecule 
phosphorylated from sphingosine, and binds to either one of five specific G protein-coupled receptors. 
These coupled receptors are responsible for the activation of the ERK pathway. Previous reports have 
revealed EVT cells promote the expression of S1P receptors, thereby permitting the regulation and 
migration of trophoblast cells via S1P receptors. Nevertheless, a lack of information exists on the influence 
of S1P on EVT cell invasion (Yang et al., 2014). 
 
1.3.2.2 Inhibitors of MEK-1 
 
EVT cell migration is inhibited by S1P via S1PR2, sphingosine-1-phosphate receptor 2 (Yang et al., 2014). 
S1PR2 is one of the G-protein-coupled receptors that are fundamentally involved in inhibiting angiogenesis 
and maintaining vascular stability. An earlier study has shown that activated S1PR1 can promote 
trophoblast invasion (Harapan and Andalas, 2015).  
Cyclin dependant kinases (CDKs) play a significant role in regulating the cycle of cell progression (Shaul 
and Seger, 2007). Many studies have postulated that CDK1 and CDK5 are able to phosphorylate MEK-1, 





thereby having an influence on MEK-1 activity, indicating that CDK phosphorylation inhibits MEK-1 
(Shaul and Seger, 2007). 
The predisposing factors to PE development as illustrated in figure 4 include immune maladaptation, 
inflammatory response and cytokine dysregulation. However, regarding HIV-associated PE, the innate 
immune response is the most significant (Bounds et al., 2015). 
Pre-existing endothelial dysfunction 
(obesity, age, hypertension, family history) 
concurrent with pregnancy 
 
 
Stimulation of innate immune response and cytokine signaling 
(STAT-3 and MEK-1) 
 
 




                                                              PRE-ECLAMPSIA DEVELOPMENT 
Figure 4: Schematic of factors involved in pre-eclampsia development (adapted from Bounds et al., 
2015) 
 
1.4 Aims and objectives  
Research on serum markers with decent detection rates can pave the way for prevention strategies; and 
therefore improved overall antenatal and perinatal care. Therefore, this study targeted how stress and 
signaling pathways influence villous trophoblastic function in distinct subforms of pre-eclampsia by the 





investigation of kinases involved in the regulation of cell survival, proliferation, differentiation, apoptosis, 
and the release of inflammatory mediators and antiangiogenic factors.  
Since apoptosis is elevated in pre-eclampsia, the aim of this study is to investigate the role of cell signalling 
analytes viz., STAT-3 and MEK-1 in HIV-associated pre-eclampsia and normotensive patients using the 
Bio-Plex Multiplex Immunoassay.  
Objectives of this study include:    
• To investigate STAT-3 and MEK-1 expression across all study groups using BioPlex      
              Multiplex Immunoassay. 
• To compare STAT-3 and MEK-1 expression based on pregnancy type (normotensive  
              vs pre-eclamptic), regardless of HIV status. 
• To compare STAT-3 and MEK-1 expression based on HIV status (positive vs negative),  
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Objective: Regulation of trophoblast invasion is mediated through cell signaling, therefore this study 
investigated protein kinases STAT-3 and MEK-1 in HIV-associated pre-eclampsia. Method: STAT-3 and 
MEK-1 expression were analysed by Bioplex immunoassays in 80 normotensive and pre-eclamptic women 
stratified by HIV status. Results: STAT-3 expression differed by pregnancy type (p=0.001) and not HIV 
status (p=0.0859), while MEK-1 differed by HIV status (p=0.0102) and not pregnancy type (p=0.1526). 
Conclusion: This study demonstrates a downregulation of STAT-3 and MEK-1 in pre-eclampsia, 
corroborating limited trophoblast invasion. HAART and non-phosphorylation of HIV regulatory proteins 
may account for the downregulation of STAT-3 and MEK-1, respectively 
Keywords: Pre-eclampsia, HIV, STAT-3, MEK-1, HAART  


















South Africa has the highest prevalence (12.7%) of HIV/AIDS in the world, with 7.03 million of the 
population being HIV positive (1). The HIV prevalence amongst antenatal women is 29.5%, hence an 
obstetric predicament. KwaZulu-Natal Province is regarded as the epicentre of this health burden, with an 
HIV prevalence rate of > 30% (2). 
Research has shown a possible link between HIV and pre-eclampsia (PE) probably because of the immuno-
depressive effects of HIV infection (3). Pre-eclampsia is a multisystem disorder complicating 5-10% of all 
pregnancies globally and accounts for considerable maternal and neonatal morbidity and mortality 
worldwide (4). Pre-eclampsia is characterized by sustained new onset high blood pressure (BP) (≥140/90 
mmHg) and   proteinuria (≥300mg protein) after 20 weeks gestational age (5). Because the exact aetiology 
of PE is unknown, clinical management is empiric and cure is achieved by delivery of the baby and the 
placenta (4).   
Given the high frequencies of HIV infection and PE in South Africa, and the fact that both disorders are 
associated with changes to the immune system mainly a decreased cell mediated immunity and an 
exaggerated inflammatory response respectively, it seems reasonable to assume that opposing immune 
responses maybe neutralised (6). This decrease in cell mediated immunity in HIV infection can largely be 
contributed to the widespread use of highly active antiretroviral therapy (HAART) (7). HAART is 
successfully involved in the reduction of plasma HIV-1 viral load, rates of vertical transmission and delayed 
response of viral resistance in pregnancy (8, 9). Also, studies have shown that HIV-positive pregnant 
women not receiving antiretroviral therapy (ART), are less inclined to develop PE compared to those on 
HAART (10). According to Wimalasundera et al, 2002 a suppressed immune response in HIV-1 infection 
associated with a decreased CD4 cell count, may elucidate the low rate of pre-eclampsia development in 
untreated HIV-positive pregnant women. The association between PE and HIV/AIDS in South Africa 
provides the perfect backdrop for studies in this disease duality.  





Pre-eclampsia is associated with poor placentation and uterine spiral artery remodeling which results in 
placental hypoxia and localized oxidative stress due to a state of under-perfusion (11). This leads to an 
exacerbated systemic inflammatory response as a result of defective trophoblast invasion to promote spiral 
artery remodeling (12). Defective trophoblast invasion leads to the release of excretory factors from the 
maternal circulation culminating in an enhanced maternal inflammatory response and of the pathognomonic 
endothelial cell lesion (13).  
The migratory and invasive properties of extravillous trophoblast cells (EVT) are functionally controlled 
by many cytokines and growth factors that signal through the Janus kinase-signal transducer and activator 
of transcription (JAK-STAT) pathway (14). The STAT-3 activating subunit, a member of the STAT 
mammalian family, plays a fundamental role in trophoblast invasion in vitro as phosphorylated STAT-3 
enhances the invasive capabilities of trophoblast cells, a significant requirement for a successful pregnancy 
(15).  
The mitogen activated protein kinase (MAPK) pathway is constituted of three protein kinase tier cascades 
(16). The extracellular regulated kinase (ERK) cascade is the main downstream component of the MAPK 
pathway (17). ERK is activated by dual specificity kinases MEK-1 and MEK-2. Activated ERK induces 
cell proliferation, differentiation and development and under certain conditions, cell survival, migration and 
apoptosis (18). MEK-1 regulates EVT invasive capabilities by various growth and regulatory factors within 
the microenvironment of the uterine endometrium and decidua (19).  
Since STAT-3 AND MEK-1 are contributing factors in the invasion of trophoblast cells it is vital that their 
expression levels are examined in HIV-associated PE (13). Hence this study will focus on cell signalling 
analytes viz., STAT-3 and MEK-1 in women based on pregnancy type (normotensive vs pre-eclamptic) and 
HIV status (HIV+ve vs HIV–ve). 





Methods and materials 
Study population 
Ethics approval (BE210/17) and regulatory health authority permission were obtained. Pregnant women 
were purposively recruited from the antenatal clinic at a large district hospital in Durban, SA. The study 
population (n=80) determined by Fischer’s test, consisted of a normotensive pregnant group (n=40) and a 
PE group (n=40). Each group was further stratified by HIV status into (1) HIV-positive normotensive 
(n=20); (2) HIV-negative normotensive (n=20); (3) HIV-positive PE (n=20) and (4) HIV-negative PE 
(n=20). Pre-eclampsia was defined as systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 
mmHg with at least a two plus of proteinuria on dipstick testing after 20 weeks of pregnancy. The HIV 
status was determined by two rapid bed-side tests and CD4 counts were performed if the woman was HIV-
positive. All newly diagnosed HIV-positive women were initiated on combined anti-retroviral therapy. 
Exclusion criteria was based on patients that declined participation and those with chorioamnionitis, 
eclampsia, polycystic ovarian syndrome, abruption placentae, intrauterine death, sickle cell disease, chronic 
renal disease, cardiac disease, unknown HIV status, pre-existing seizure disorders, asthma and patients that 
are not booked into the hospital.  
Following written informed consent, venous blood samples were collected in K3-EDTA tubes, buffy coat 
extracted and stored in cryovials at -80°C until immunoassay. 
Bio-Plex Multiplex immunoassay 
The buffy coat (leucocyte suspension) was used to assess differences in median fluorescent intensity (MFI) 
of phosphorylated STAT-3 (S727) (1:4 dilution) and phosphorylated MEK-1 (S217/221) (1:4 dilution) 
using the Bio-Plex® ProTM  cell signaling MAPK Panel 2-Plex assay (catalogue #LQ0-0000S6KL81S; Bio-
Rad Laboratories Inc., South Africa). This immunoassay was performed according to the manufacturer’s 
instructions.  





This assay follows a similar technique to that of a sandwich ELISA, following incubation of antigen 
samples in the study viz., STAT-3 and MEK-1 with the capture antibody-coupled magnetic beads. 
Biotinylated detection antibodies were added to the reaction, along with a reporter conjugate, streptavidin-
phycoerythrin conjugate (SA-PE). After washing, detection of the reaction was carried out using Bio-
Plex®MAGPIXTM Multiplex Reader (Bio-Rad Laboratories Inc., USA). The fluorescence of the SA-PE 
bound to each bead is measured by the reader. Data from the Bio-plex multiplex analysis was obtained 
using the Bio-Plex ManagerTM software version 4.1.  
The measurement of analyte expression for a given bead population in each study group was provided as 
the median fluorescent intensity (MFI). The relative concentration of analyte bound to each bead is equal 
to the MFI.  
Statistical analysis 
Data was analysed using GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, California 
USA). Statistical analysis across all groups of the sample population were based on HIV status and 
pregnancy type, using a One-way ANOVA and the Bonferroni post hoc multiple comparison test. The level 
of significance was considered as a probability level of p < 0.05. For individual analysis, a student’s t-test 
was performed.  
Results 
Clinical characteristics and demographic data 
As seen in table 1 across the study groups, a significant difference was detected for gestational age (p < 
0.001) and systolic and diastolic BP (p < 0.001). Maternal age, gestational age, parity, systolic and diastolic 
BP and maternal weight were similar between HIV-positive vs HIV-negative groups (p < 0.05). Albeit non-
significant, parity (2.0±0.21 vs 1.6±0.15; p > 0.2370); systolic BP (131±4.5 vs 130±5.4mmHg; p > 0.6543) 
and diastolic BP (85±2.9 vs 83±4.0mmHg; p > 0.9005) were elevated in HIV-positive vs HIV-negative 
women. 





Statistical significance was detected for gestational age (p = 0.0009), parity (p = 0.0401) and systolic and 
diastolic BP (p < 0.0001). Maternal age (30±2.5 vs 28±0.91years; p = 0.8105); parity (2.0±0.17 vs 1.5±0.19; 
p = 0.0410); systolic BP (154±2.4 vs 109±3.7mmHg; p ˂ 0.0001); diastolic BP (100±1.3 vs 69±2.8mmHg; 
p < 0.0001) and maternal weight (85±2.9 vs 80±2.0kg; p = 0.1931) were higher in pre-eclamptic vs 
normotensive pregnancies.   
Table 1: Clinical profile and demographic data of participants across all study groups. 







pre - eclamptic 
 







28±1.2 28±1.4 30±4.4 31±1.8 0.8534 
Gestational 
Age (weeks) 
38±0.25 38±0.27 36±0.77 34±1.1 0.0003 (***) 
 
Parity 1.4±0.22 1.6±0.3 1.8±0.2 2.4±0.27 0.0815 
Systolic BP 
(mmHg) 
108±6.8 111±1.9 154±3.1 154±3.8 ˂0.0001(***) 
Diastolic BP 
(mmHg) 
66±5.1 72±1.3 100±1.8 100±2.1 ˂0.0001(***) 
Weight (kg) 80±2.5 80±3.2 88±3.4 81±4.9 0.3322 
Mean ± SEM are presented; One-way ANOVA and the Bonferroni post hoc multiple comparison test was used for 
statistical analysis, n = 80 ***p < 0.001 
Cell signaling analytes  
STAT-3 expression:  
HIV status: As seen in figure 1A, based on HIV status, no significant difference (p = 0.09) was detected for 
STAT-3 expression between HIV-positive and HIV-negative groups (110 ± 9.3 vs 140 ± 12 MFI).  





Pregnancy type: A level of significance (p < 0.05) was detected for STAT-3 expression between pre-
eclamptic and normotensive (95 ± 6.5 vs 150 ± 11 MFI) pregnancies (Figure 1B). 
Across study groups: Figure 1C illustrates STAT-3 expression across all study groups; been significantly 
different (p < 0.05) between HIV-positive normotensive vs HIV-negative normotensive participants (118 ± 
14 vs 180 ± 12 MFI); HIV-negative pre-eclamptic vs HIV-negative normotensive participants (91 ± 9.8 vs 
180 ± 12 MFI)  and HIV-positive pre-eclamptic vs HIV-negative normotensive (100 ± 8.8 vs 180 ± 12 
MFI). The level of STAT-3 were similar between HIV-negative pre-eclamptic vs HIV-positive 
normotensive participants, HIV-positive pre-eclamptic vs HIV-positive normotensive participants and 




















































Figure 1: STAT-3 expression: (A) based on HIV status; no significance (ns) (B) based on pregnancy 
type; ***p < 0.01 and (C) across all study groups; **p < 0.01 ***p < 0.001. Results are represented 

















































MEK-1 expression:  
HIV status: In figure 2A, based on HIV status and regardless of pregnancy type, a significant difference (p 
= 0.0102) in MEK-1 expression was noted between HIV-positive and HIV-negative groups (17 ± 0.58 vs 
24 ± 1.9 MFI).  
Pregnancy type: Based on pregnancy type as seen in figure 2B, no significant difference (p = 0.1526) was 
detected for MEK-1 between pre-eclamptic and normotensive pregnancies (19 ± 1.3 vs 21 ± 1.5 MFI). 
Across study groups: Figure 2C illustrates MEK-1 expression across all study groups; been significantly 
different (p < 0.001) between HIV-positive normotensive vs HIV-negative normotensive participants (17 ± 
0.61 vs 30 ± 2.7 MFI); HIV-positive pre-eclamptic vs HIV-negative normotensive participants (17 ± 1.3 vs 
30 ± 2.7 MFI). A level of significance (p < 0.05) was detected between HIV-negative pre-eclamptic 
participants vs HIV-negative normotensive participants (20 ± 2.0 vs 30 ± 2.7 MFI). No significance was 
detected between HIV-negative pre-eclamptic vs HIV-positive normotensive participants, HIV-positive 













































Figure 2: MEK-1 expression: (A) based on HIV status; *p < 0.05 (B) based on pregnancy type; no 
significance (ns) and (C) across all study groups; **p < 0.01; ***p < 0.001. Results are represented 
as mean ± SEM. 
Discussion 
The expression of protein kinases STAT-3 and MEK-1 are responsible for cytokine signaling hence vital 













































In our study, there was an upregulation of STAT-3 expression based on pregnancy type irrespective of HIV 
status in normotensive participants compared to pre-eclamptic participants. These results were similar to 
the findings of (Zhang et al, 2015). In normal pregnancy, the influential role of cytokines in the modulation 
of trophoblast cell proliferation and migration, are dependent on the STAT-3 subunit of the JAK-STAT 
pathway for their signaling to facilitate normal placentation (14).  
It is therefore plausible to assume that a defect of STAT-3 activity caused by negative regulators of the 
JAK-STAT pathway contribute to the defective trophoblast invasion in pre-eclampsia. Some of these 
regulators include the suppressor of cytokine signaling (SOCS) proteins, the protein inhibitor of activated 
STAT (PIAS) and protein tyrosine phosphates (PTPs) (23). SOC proteins are immunolocalized in the 
syncytiotrophoblasts (24) and it is postulated that a decrease in SOC activity in gestation may influence the 
overexpression of SOCS in pre-term labour (25). 
In our study, STAT-3 expression was similar between HIV-positive vs HIV-negative groups, irrespective 
of pregnancy type. It is important to note that all infected participants in our study were on dual therapy for 
HIV infection, namely nevirapine and HAART.  Our results however, did indicate a downregulation trend 
of STAT-3 expression in HIV-positive vs HIV-negative participants, as it has been established that STAT-
3 plays a significant role in the regulation of the development, activation and physiology of dendritic cells 
(DC) (26, 27). Upon recognition of pathogens such as the HIV virus, dendritic cells are involved in 
connecting the innate and adaptive immune system to initiate an appropriate immune response (28). 
However, once HIV infection is initiated, the virus negatively influences DC function, thereby interfering 
the mechanisms linking innate and adaptive immunity (29, 30). 
This downregulatory trend of STAT-3 in HIV-positive patients may also be attributed to HAART as studies 
have shown an increased predisposition to pre-eclampsia development in infected patients receiving 
HAART (6). Regardless of the conflicting data between HIV and pre-eclampsia, HIV-infected women 
without HAART have a weakened immune response and are therefore less likely to uphold the exacerbated 





immune response in pre-eclampsia (10), due to the consensus that both conditions are linked to an 
exaggerated inflammatory response (31).  
Previous studies have reported that a contributing factor to the systemic inflammatory response in pre-
eclampsia are elevated levels of IL-6, which signals through the JAK-STAT pathway. HIV-positive 
individuals overproduce IL-6 and other pro-inflammatory cytokines (32). In HIV-positive pregnant 
participants receiving ARVs, the expression of IL-6 messenger (m)RNA (33) and IL-6 production are 
reduced, thereby supporting immune reconstitution with an increased predisposition to pre-eclampsia 
development. Also, STAT-3 can mediate the regulation of DC to assist in minimizing the 
immunosuppressive effects of HIV and further opportunistic infections, despite lower levels of STAT-3 in 
influencing trophoblast invasion. 
Some early studies have demonstrated that an absence of STAT-3 expression in hematopoietic progenitors 
led to a major deficiency of DC cells (34) and DC differentiation and maturation from hematopoietic 
precursors were also affected (35). Therefore, in HIV-negative individuals, STAT-3 expression is vital to 
effectively influence DC function in comparison to the immunocompetence in the failing immune system 
of an HIV-positive individual, as HIV infection results in the progressive decrease of CD4+ T lymphocytes 
and the deteriorating response of CD4+ and CD8+ T-cells towards HIV and other invading pathogens (36). 
The lower STAT-3 expression in HIV-positive women on HAART in our study suggests that despite the 
minimal viremia in patients receiving HAART, persistence of the HIV virus continues as a result of latent 
provirus replication in resting memory CD4+ T cells in the peripheral blood (37). A defect in STAT-3 and 
its role in DC function can be further attributed to the persistence of HIV infection.  
In the current study, similar to STAT-3, MEK-1 expression was not different between the normotensive 
and pre-eclamptic cohorts. The lower MEK-1 expression in pre-eclamptic vs normotensive participants 
corroborates its role in promoting trophoblast invasion (19). 





Extravillous (EVT) cells promote the expression of sphingosine-1-phosphate (S1P) receptors, a signaling 
molecule phosphorylated from sphingosine, which binds to one of five specific G protein-coupled receptors 
(38, 39). These coupled receptors are responsible for the activation of the ERK pathway (40, 41). Inhibition 
of the MEK-1 constituent by S1P via S1PR2, sphingosine-1-phosphate receptor 2, can hinder EVT cell 
migration (19) a major contributing factor to the defective trophoblast invasion that characterizes pre-
eclampsia.  
In our study, based on HIV status, MEK-1 expression was downregulated in HIV-positive vs HIV-negative 
participants regardless of pregnancy type. In contrast to our findings, an upregulation of MEK-1 expression 
has been reported in HIV-positive HAART naïve patients (Yang and Gabuzda, 1999 and Alhetheel et al, 
2013). The activation of the MAPK pathway by mitogens and additional extracellular stimuli contribute to 
the activation of HIV-1 replication, by enhancing the pathogenic abilities of HIV-1 virions (42). This 
suggests that untreated HIV-positive patients have elevated levels of MEK-1 expression. 
Furthermore, activated MAPKs result in the phosphorylation of HIV regulatory proteins viz., Vif, Rev, Tat, 
Nef, and p17, thereby enhancing viral replication (43). These viral proteins activate a variety of other cell 
signaling molecules to support replication of the virus (44). Nef and Tat mimic T-cell signaling pathways 
in the early stages of infection, sustaining replication of the virus in infected T-cells (44). Nef also 
contributes to the downregulation of CD4 (45) and CD28 cell surface receptors (46); and class I, A and B 
of the major histocompatibility complex (MHC) (47). Tat viral protein plays a role in viral transcription 
(48) and has been shown to upregulate  IL-10, resulting in the increased production of IL-10 in HIV-positive 
patients (49). 
Furthermore, MAPK modulates the function of monocytes, lymphocytes and apoptosis during HIV 
infection (50), thus phosphorylation of the MAPK pathway is less heightened in treated HIV-positive 
patients adhering to HAART, due to improvement in the recovery of CD4+ T cell function,  reduced HIV-
1 replication with an increase in CD4+ T cell count (51).  





Additionally, the inhibition of MEK-1 by a MAPK inhibitor hinders MAPK activation, as well as MAPK 
substrate phosphorylation, subsequently resulting in diminished viral replication (52). The inhibition of 
HIV-1 infection is mediated by obstructing activation of the MAPK pathway, rather than a reduced 
expression of MAPKs (43). These results collectively suggest that MAPKs and their constituents modulate 
the infective capabilities of HIV-1 virus particles (43).  
Conclusion 
This study demonstrates a significant downregulation of STAT-3 and MEK-1 in pre-eclampsia compared 
to normotensive pregnancies. These results account for the decreased trophoblast migration that 
characterizes PE. In our study, the HAART regimen supports the decline of STAT-3 expression in HIV-
positive women. However, contrary to expected outcomes, MEK-1 expression was downregulated in HIV 
infection, possibly due to the non-phosphorylation of the HIV accessory proteins. However, more studies 
need to be conducted on the effect of signal transduction pathways to further elucidate the effect of HAART 
on PE development. Additionally, the detection of STAT-3 and MEK-1 cell analytes can serve as predictive 
biomarkers for the development of this hypertensive disorder.  
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In sub-Saharan Africa, HIV infection and maternal mortality is a serious public health concern, since more 
than one third (34.7%) of maternal deaths emanate from HIV infection in pregnancy (Saving Mothers 
Report, 2013). In contrast, the global proportion of maternal deaths caused by HIV/AIDS ranges from 7%-
21% (Zaba et al., 2013). Current studies have debated whether the progression of HIV infection may be 
accelerated by pregnancy or if HIV-positive women have a higher pre-disposition to obstetric complications 
such as pre-eclampsia (Mattar et al., 2004). Pre-eclampsia is a multisystem hypertensive disorder and some 
epidemiological findings favour a genetic and immunological etiology (Uzan et al., 2011). In KwaZulu-
Natal, South Africa, the incidence of pre-eclampsia is 12% (Saving Mothers Report, 2013).  
This study demonstrates a decrease of STAT-3 and MEK-1 in pre-eclampsia compared to normotensive 
patients irrespective of HIV status, corroborating the roles of STAT-3 and MEK-1 in trophoblast invasion 
and subsequent arterial remodelling of the maternal spiral arteries.  
Activation of STAT-3 occurs at tyrosine 705 in the C-terminal domain and its phosphorylation is caused 
by 40 different polypeptide ligands (Siveen et al., 2014). Phosphorylation of MEK-1 is activated by ERK 
and occurs on Ser218 and Ser222 in the MEK-1 activation loop within a Ser–Xaa–Ala– Xaa–Ser/Thr motif 
(Alessi et al., 1994). The consequences of phosphorylation inhibition support aberrant protein activation 
thus accounting for the trophoblast invasion that occurs in our PE group.  
It is well known that both STAT-3 and MEK-1 enhance trophoblast invasion through their respective signal 
transduction pathways in normal pregnancies (Suman et al., 2009), however a downregulation of both 
analytes contribute to pre-eclamptic development as a result of defective transformation of the maternal 
spiral arteries by shallow trophoblast invasion.  Apart from extracellular stimuli, trophoblast migration and 
invasion are influenced by cytokines, oxygen tension, growth factors and immune cells including decidual 
and uterine natural killer cells (Whitley and Cartwright, 2010). The underlying cause of the 
pathophysiology of pre-eclampsia is defective placentation, attributed to decreased myometrial 





cytotrophoblast invasion with consequential non-physiological conversion of the spiral arteries. The 
resultant ischaemic microenviroment causes oxidative stress with  an expulsion of specific molecules into 
the maternal circulation, that leads to the development of symptomatic systemic inflammation and 
endothelial dysfunction (Yeh et al., 2012).  
In our study, the decreased expression of STAT-3 and MEK-1 in pre-eclamptic pregnancies may be 
attributed to the reduced expression of an upstream gene or protein unable to optimize phosphorylation. 
The cytokine IL-6 is able to increase STAT-3 phosphorylation (Zhang et al., 2015). Our results implicate 
a low expression of IL-6 in HIV-positive patients on HAART, suggesting non-phosphorylation of STAT-
3. On the contrary, restoration of the immune response through the benefits of HAART provides a thriving 
opportunity for pre-eclampsia development, in counteracting the physiology of T-cells in the progression 
of HIV infection.  
Based on HIV status, both STAT-3 and MEK-1 were downregulated in HIV-positive women, possibly due 
to HAART and non-phosphorylation of HIV regulatory proteins. The elevated STAT-3 expression in HIV-
negative women, supports the influence of STAT-3 in combatting HIV infection due to its role in dendritic 
cell (DC) function.  
In response to HIV-1 infection and HAART, STAT-3 plays a significant role in the adaptive immune 
response, in mediating the physiology of DCs. In spite of CD4+ T-cells being the prominent target for HIV 
infection, DCs are highly influential in the transmission of the virus, infection of target cells and HIV 
antigen presentation (Manches et al., 2014). The potential deficit of DCs in HIV-1 infection may correlate 
with the decreased T-cell response and type-1 cytokine secretion that contributes to the increased 
susceptibility to opportunistic infections (Chehimi et al., 2002). Noteworthy, the STAT-3 expression in 
infected patients on HAART confers immune reconstitution and moderates viral progression via DC 
function. However, a defect in STAT-3 could impede DC function, supporting persistence of viral infection 





(Nefedova et al., 2005). In untreated patients, it is presumed that STAT-3 expression is lower compared to 
those on HAART (Chehimi et al., 2002).  
Depending on the type of virus, gene transcription mediated by STAT-3 can either be promoted or 
disrupted. Inhibition of STAT-3 signaling by suppressors of cytokine signaling (SOCS) appears to be a 
strategic mechanism of viruses to circumvent host immune responses, as a result of SOCS overexpression 
(Mohan et al., 2007). SOCS3 transcription is activated by STAT-3, preventing STAT-3 signaling by JAKs 
inhibition (Carow and Rottenberg, 2014). The presence of SOCs in the JAK/STAT pathway can further 
validate the downregulation of STAT-3 in HIV-positive women. SOCS3 and STAT-3 compete for pY-
binding sites on activated receptor chains, or through the binding of signaling proteins for proteasomal 
degradation (Robinson et al., 2013; Koskela et al., 2012).  
Moreover, an overexpression of STAT-3 inhibits cell apoptosis and in turn promotes cell growth and 
survival (Yin et al., 2011), thereby promoting regular trophoblast invasion within the placental bed (Zhang 
et al., 2015). Both STAT-3 and a downstream component of the MAPK pathway, the early growth response 
protein 1 (Egr-1) concomitantly regulate cell growth and apoptosis (Chatterjee et al., 2007).  
Each cascade of the activated MAPK pathway viz., ERK, JNK and p38 enhance the gene expression level 
of the HIV virion, replication level of the viral genome and infection activity (Krens et al., 2006; Yang and 
Gabuzda, 1998; Seger and Krebs, 1995). Moreover, HIV-1 infection activates the MAPK signaling pathway 
by phosphorylation of HIV viral proteins, Tat, Nef and gp120.  
HIV-1 viral proteins also modify various transcription factors and infected CD4+ T cell surface receptors 
to facilitate HIV-1 infection and pathogenesis (Abbas and Herbein, 2013). As a result, low MEK-1 
expression may be expected in HIV-positive patients on HAART due to the improvement of CD4 counts, 
control of viremia and a declined systemic immune response to HIV (Mkhize et al., 2010). HAART hinders 
MEK-1 functioning thus suppressing HIV replication and promoting restoration of CD4 T-cell counts in 
HIV infected patients (Tincati et al., 2009).  





Moreover, in untreated HIV-1 infection, the exaggerated immune response through an increasing T-cell 
turnover, elevated levels of pro-inflammatory cytokines and polyclonal activation of B-cells (Sodora and 
Silvestri, 2008) provides opportunity for overexpression of MEK-1 through activation of the MAPK 
pathway. As such, the over expression of MEK-1 in HIV-infection is critical in enhancing viral replication. 
Inhibition of MEK-1 phosphorylation by MAPK inhibitors, and subsequently ERK1/2 activation suggests 
suppressed viral replication (Dudley et al., 1995), although further insight is required into MAPK inhibitors. 
All HIV-positive women in our study adhered to the HAART regimen, as part of the standard of care 
treatment regimen in South Africa. This may be considered one of the limitations of our study, as 
differences in analyte expression based on HIV status is confounded by HAART regimen.  
Conclusion: 
Our study demonstrated the downregulation of STAT-3 and MEK-1 in pre-eclampsia compared to 
normotensive pregnant women, verifying the significance of these analytes in trophoblast invasion and non-
conversion of the maternal spiral arteries for a successful pregnancy. The downregulation of STAT-3 in 
HIV-positive women may be attributed to low levels of IL-6 responsible for non-phosphorylation of STAT-
3. In addition, HAART may be a contributing factor of STAT-3. Contrary to expected outcomes, the 
decreased expression of MEK-1 in HIV-positive women could be attributed to the non-phosphorylation of 
HIV regulatory proteins or the inhibition of the MAPK pathway by MAPK inhibitors. Although a consensus 
has yet to be elucidated between the role of antiretroviral therapy and HAART towards pre-eclampsia 
development, the emergence of novel non-invasive markers for early detection are useful to provide an 
improved patient management for both mother and fetus, thus potentially reducing maternal and fetal 
mortality and morbidity rates worldwide. 
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